Genetic Risk Factors for End-Stage Hip Osteoarthritis Treated with Total Hip Arthroplasty: A Genome-Wide Association Study.

Overview

BACKGROUND: Although a genetic component to hip osteoarthritis (OA) has been described, focused evaluation of the genetic components of end-stage disease is limited. We present a genome-wide association study for patients undergoing total hip arthroplasty (THA) to characterize the genetic risk factors associated with end stage hip osteoarthritis (ESHO), defined as utilization of the procedure. METHODS: Patients who underwent primary THA for hip OA were identified in a national patient data repository using administrative codes. 15,355 patients with ESHO and 374,193 control patients were identified. Whole genome regression of genotypic data for patients who underwent primary THA for hip OA corrected for age, sex, and body mass index (BMI) was performed. Multivariate logistic regression models were used to evaluate the composite genetic risk from the identified genetic variants. RESULTS: There were 13 significant genes identified. Composite genetic factors resulted in an odds ratio 1.04 for ESHO (P<0.001). The effect of genetics was lower than that of age (Odds Ratio (OR): 2.38; P<0.001) and BMI (1.81; P<0.001). results CONCLUSIONS: Multiple genetic variants, including five novel loci, were associated with end-stage hip OA treated with primary THA. Age and BMI were associated with greater odds of developing end-stage disease when compared to genetic factors.